DNLI
Denali Therapeutics Inc.Company Information
- Company Name
- Denali Therapeutics Inc.
- CIK
- CIK0001714899
- Category
- Large accelerated filer
- Ticker: Exchange
- DNLI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- DNLI
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 71,134
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 137,534,950
- Shares outstanding
- 187,314,501
- Ownership
- 73.42%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -2.95%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Nonrelated Party | - | - | - | - | - | - | - | - | - | - | - | -7 | ||||||
| Related Party | - | - | - | - | - | - | - | - | - | - | - | -7 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 202 | 388 | 205 | 91 | 141 | 57 | 175 | 91 | 75 | 61 | 127 | 148 | ||||||
| Marketable Securities Current | 509 | 600 | 663 | 757 | 758 | 761 | 657 | 746 | 821 | 876 | 907 | 961 | ||||||
| Accounts Receivable Net Current | 4 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Inventory Net | 4 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 35 | 35 | 33 | 34 | 36 | 61 | 32 | 32 | 32 | 37 | 30 | 34 | ||||||
| Assets Current | 754 | 1,023 | 901 | 883 | 935 | 879 | 864 | 869 | 928 | 974 | 1,064 | 1,143 | ||||||
| Marketable Securities Noncurrent | 230 | 64 | 98 | 25 | 78 | 236 | 359 | 445 | 451 | 491 | 0 | 8 | ||||||
| Property Plant And Equipment Net | 50 | 52 | 52 | 54 | 59 | 58 | 55 | 51 | 48 | 47 | 46 | 48 | ||||||
| Finance Lease Right Of Use Asset | 47 | 48 | 49 | 49 | 50 | 50 | 48 | 39 | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 25 | 26 | 27 | ||||||
| Intangible Assets Net Excluding Goodwill | 35 | 36 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 26 | 26 | 26 | 25 | 23 | 27 | 25 | 26 | 51 | 45 | 18 | 11 | ||||||
| Assets | 1,158 | 1,266 | 1,145 | 1,056 | 1,166 | 1,271 | 1,374 | 1,454 | 1,503 | 1,581 | 1,154 | 1,237 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 12 | 40 | 3 | 7 | 11 | 8 | 11 | 10 | 14 | 12 | 9 | - | ||||||
| Employee Related Liabilities Current | - | 9 | - | 18 | 12 | 8 | - | 15 | 10 | 8 | - | 16 | ||||||
| Accrued Liabilities Current | 78 | 70 | 95 | 5 | 7 | 7 | 91 | 5 | 6 | 6 | 68 | - | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Liabilities Current | 90 | 110 | 98 | 90 | 91 | 92 | 102 | 87 | 75 | 83 | 78 | 71 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Operating Lease Liability Current | - | 10 | - | 9 | 9 | 9 | - | 8 | 8 | 8 | - | 7 | ||||||
| Operating Lease Liability Noncurrent | 22 | 25 | 27 | 30 | 32 | 34 | 37 | 39 | 41 | 43 | 45 | 47 | ||||||
| Finance Lease Liability Noncurrent | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | - | - | 0 | - | ||||||
| Liabilities | 323 | 340 | 131 | 129 | 139 | 149 | 144 | 136 | 116 | 126 | 123 | 118 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Value Outstanding | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | - | ||||||
| Additional Paid In Capital | 3,143 | 3,105 | 3,063 | 2,846 | 2,820 | 2,791 | 2,765 | 2,735 | 2,705 | 2,673 | 2,145 | 2,114 | ||||||
| Common Stock Value | - | - | - | - | - | - | - | - | - | - | 2 | 2 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -1 | 1 | 1 | 1 | 2 | 2 | 6 | -3 | -1 | 1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -2,308 | -2,180 | -2,052 | -1,923 | -1,796 | -1,672 | -1,539 | -1,424 | -1,317 | -1,218 | -1,116 | -997 | ||||||
| Stockholders Equity | 835 | 926 | 1,014 | 926 | 1,027 | 1,123 | 1,230 | 1,318 | 1,387 | 1,455 | 1,031 | 1,118 | ||||||
| Liabilities And Stockholders Equity | 1,158 | 1,266 | 1,145 | 1,056 | 1,166 | 1,271 | 1,374 | 1,454 | 1,503 | 1,581 | 1,154 | 1,237 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 160 | 159 | 156 | 147 | 146 | 145 | 144 | 144 | 143 | 143 | 138 | 138 | ||||||
| Shares Outstanding | 160 | 159 | 156 | 147 | 146 | 145 | 144 | 144 | 143 | 143 | 138 | 138 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDenali Therapeutics Inc. (DNLI) — SEC Financial Statements & Analysis
Denali Therapeutics Inc. (DNLI) is a biological products, (no diagnostic substances) company, incorporated in DE. Denali Therapeutics Inc. trades on Nasdaq as: DNLI. Denali Therapeutics Inc. (DNLI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Denali Therapeutics Inc. carries a market cap of $4.82B, a P/E ratio of -9.42x, a P/B ratio of 5.77x, a P/S ratio of 1336.77x, an enterprise value of $4.62B, and an EV/EBITDA multiple of -8.71x. On profitability, it posts an operating margin of -15058.19%, a net margin of -14191.20%, a Return on Equity (ROE) of -54.93%, a Return on Assets (ROA) of -44.01%, and a Return on Invested Capital (ROIC) of -71.20%. Per share, it reports EPS of $-2.73, diluted EPS of $-2.73, free cash flow per share of $-2.35, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 6.77% year-over-year, and EPS growth of -2.28% year-over-year. On the balance sheet, it maintains a current ratio of 8.37x, a quick ratio of 7.93x, working capital of $663.84M, a debt-to-equity ratio of 0.39x, a debt ratio of 0.28, free cash flow of $-440.21M (TTM), and net debt of $-199.16M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.82B
- P/E TTM
- -9.42x
- EPS TTM
- $-2.73
- P/B TTM
- 5.77x
- ROE TTM
- -54.93%
- ROA TTM
- -44.01%
- Debt To Equity
- 0.39x
- Free Cash Flow TTM
- $-440.21M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Denali Therapeutics Inc. in?
Denali Therapeutics Inc. (DNLI) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does DNLI trade on?
Denali Therapeutics Inc. (DNLI) trades on the Nasdaq.
Where is Denali Therapeutics Inc. incorporated?
Denali Therapeutics Inc. is incorporated in DE.
When was Denali Therapeutics Inc. (DNLI)'s most recent SEC filing?
Denali Therapeutics Inc. (DNLI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is DNLI's market cap?
Denali Therapeutics Inc. (DNLI) has a market capitalization of $4.82B as of 2026-06-30.
What is DNLI's EPS (earnings per share)?
Denali Therapeutics Inc. (DNLI)'s trailing twelve month EPS is $-2.73 as of 2026-06-30.
What is DNLI's ROE (return on equity)?
Denali Therapeutics Inc. (DNLI)'s trailing twelve month Return on Equity (ROE) is -54.93% as of 2026-06-30.
What is DNLI's ROA (return on assets)?
Denali Therapeutics Inc. (DNLI)'s trailing twelve month Return on Assets (ROA) is -44.01% as of 2026-06-30.
What is DNLI's ROIC (return on invested capital)?
Denali Therapeutics Inc. (DNLI)'s trailing twelve month Return on Invested Capital (ROIC) is -71.20% as of 2026-06-30.
What is DNLI's EV/EBITDA?
Denali Therapeutics Inc. (DNLI)'s trailing twelve month EV/EBITDA is -8.71x as of 2026-06-30.